Overview of hurdles and advancements in utilizing advanced imaging techniques for prostate cancer diagnosis, including agent availability, scheduling, facility preferences, and reimbursement.
PREVENT trial: Transperineal biopsy lowers risk of infection vs transrectal biopsy
No patients in the transperineal cohort experienced an infection, compared with 1.6% of patients in the transrectal cohort.
Dr. Murphy on increasing diversity in cancer clinical trials
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
PEACE-1 ancillary study: Biomarkers predict prognosis but not abiraterone benefit in mCSPC
Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Radium223, chemotherapy improves mCRPC quality of life in phase 2 RAPSON
New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC
New findings from the open-label SPLASH trial show patients with mCRPC achieved improved progression-free survival as well as response rates and antigen-specific reductions.